menu
    • menu
    [{"orgOrder":0,"company":"Biogen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"PF-05251749","moa":"CK1","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0.70999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.70999999999999996,"dosageForm":"Oral","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"ST-501","moa":"Tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Biogen","amount2":2.7200000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":2.7200000000000002,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Vir Biotechnology"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Vir Biotechnology"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BIIB059","moa":"Blood dendritic cell antigen 2","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Massachusetts Eye and Ear","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"AAV gene therapy","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Massachusetts Eye and Ear","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Massachusetts Eye and Ear"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"PPAR gamma","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Blackstone","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Blackstone"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"DNL151","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":2.1499999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"DNL151","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":2.1499999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Biogen","sponsor":"Scribe Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CRISPR based gene therapy","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Biogen","amount2":0.41999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BIIB059","moa":"Blood dendritic cell antigen 2","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"ISD Immunotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"ISD-017","moa":"STING pathway","graph1":"Immunology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen Inc"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":3.1299999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":3.1299999999999999,"dosageForm":"Oral","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Giroctocogene fitelparvovec","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biogen","amount2":2.7200000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":2.7200000000000002,"dosageForm":"Intravenous infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"ViGeneron","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"VG801","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Cevec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"AAV-based gene therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"BAT1806","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CB 2782-PEG","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Capsigen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AAV capsids based gene therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":1.3100000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.3100000000000001,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"TMS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"TMS-007","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Inravenous infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cotoretigene toliparvovec","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Recombinant AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Biogen","amount2":0.12,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"NightstaRx Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Timrepigene emparvovec","moa":"Human choroideremia gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ NightstaRx Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ NightstaRx Ltd"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Gosuranemab","moa":"Tau protein","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BIIB059","moa":"Blood dendritic cell antigen 2","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Timrepigene Emparvovec","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Biogen","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.93999999999999995,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Diroximel fumarate","moa":"Nicotinic alpha 10 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vixotrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co., Ltd.","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai Co., Ltd."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Co.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co.","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai Co."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Eisai Co"},{"orgOrder":0,"company":"Biogen","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Lenalidomide","moa":"CD20","graph1":"Oncology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CB 2782-PEG","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Nephrology","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Scribe Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Expanded Collaboration","leadProduct":"CRISPR-based Therapeutic","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Biogen Inc."},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"DNL151","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Envisagenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Envisagenics","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Envisagenics"},{"orgOrder":0,"company":"Biogen","sponsor":"Feinstein Institutes","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Feinstein Institutes for Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Feinstein Institutes for Medical Research"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Denali Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Denali Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Peginterferon Beta-1a","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Glofitamab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Genentech"},{"orgOrder":0,"company":"Biogen","sponsor":"Alcyone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Divestment","leadProduct":"Etanercept","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":2.2999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Samsung Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Samsung Biologics"},{"orgOrder":0,"company":"Biogen","sponsor":"Alectos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"AL01811","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Biogen","amount2":0.71999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.71999999999999997,"dosageForm":"Oral","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Reata Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Reata Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Alcyone Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":7.2999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":7.2999999999999998,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":7.2999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":7.2999999999999998,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Fampridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Neurimmune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Termination","leadProduct":"Aducanumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0.38,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.38,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"HI-Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Biogen","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"HI-Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Biogen","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.8,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"GSK4382276A","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biogen","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.5600000000000001,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BIIB124","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"C4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Biogen","amount2":0.41999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"2","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"SAGE-324","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":1.53,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":1.53,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Neomorph","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Molecular Glue Degrader-based Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":1.45,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.45,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40L","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Nusinersen","moa":"SMN2 pre-mRNA","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ION541","moa":"Ataxin 2","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"7","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB078","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BIIB078","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"BIIB115","moa":"SMN protein synthesis","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Xbrane Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Litifilimab","moa":"BDCA2","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Royalty Pharma"},{"orgOrder":0,"company":"Biogen","sponsor":"Stoke Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Zorevunersen Sodium","moa":"Nav1.1","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.55000000000000004,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Biogen"}]

    Find Clinical Drug Pipeline Developments & Deals by Biogen

    Menu

    Biogen

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zorevunersen Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Stoke Therapeutics

                            Deal Size : $550.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biogen and Stoke Therapeutics Enter into Collaboration to Develop Zorevunersen

                            Details : The collaboration aims to support the development and commercialization of STK-001 (zorevunersen sodium), a potential first-in-class disease modifying medicine for the treatment of Dravet syndrome.

                            Product Name : STK-001

                            Product Type : Oligonucleotide

                            Upfront Cash : $165.0 million

                            February 18, 2025

                            Lead Product(s) : Zorevunersen Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Stoke Therapeutics

                            Deal Size : $550.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Litifilimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Royalty Pharma

                            Deal Size : $250.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Royalty Pharma Announces R&D Funding Collaboration with Biogen

                            Details : The collaboration aims to advance the clinical development of late-stage program BIIB059 (litifilimab). It is being evaluated for the treatment of systemic lupus erythematosus.

                            Product Name : BIIB059

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 12, 2025

                            Lead Product(s) : Litifilimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Royalty Pharma

                            Deal Size : $250.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Europe to Review Safety Data for Eisai-Biogen Alzheimer's Drug

                            Details : Leqembi (lecanemab) is an IgG1 mAb directed against aggregated soluble and insoluble forms of amyloid-beta. It is now approved for alzheimer’s disease with mild cognitive impairment.

                            Product Name : Leqembi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 31, 2025

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Leqembi IV for Early Alzheimer’s Disease

                            Details : Leqembi (lecanemab) is an IgG1 mAb directed against aggregated soluble and insoluble forms of amyloid-beta. It is now approved for alzheimer’s disease with mild cognitive impairment.

                            Product Name : Leqembi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 26, 2025

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nusinersen Sodium

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

                            Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.

                            Product Name : Spinraza

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Nusinersen Sodium

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts LEQEMBI® BLA for Subcutaneous Alzheimer’s Maintenance Dosing

                            Details : Leqembi (lecanemab) is an IgG1 mAb directed against aggregated soluble and insoluble forms of amyloid-beta. It is being investigated for alzheimer’s disease with mild cognitive impairment.

                            Product Name : Leqembi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 13, 2025

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Samsung Bioepis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Samsung/Biogen EC Nod for OPUVIZ™ Aflibercept Biosimilar

                            Details : Opuviz (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration

                            Product Name : Opuviz

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 18, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Samsung Bioepis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Eisai

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eisai Gains CHMP Opinion for Lecanemab in Early Alzheimer's Disease in EU

                            Details : Leqembi (lecanemab) selectively binds to soluble Aβ aggregates (protofibrils), as well as insoluble amyloid beta aggregates (fibrils) which are a major component of amyloid beta plaques in AD.

                            Product Name : Leqembi

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 14, 2024

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Eisai

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molecular Glue Degrader-based Therapy

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Recipient : Neomorph

                            Deal Size : $1,450.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biogen & Neomorph Announce Collaboration to Discover and Develop Molecular Glue Degraders

                            Details : The collaboration aims to leverage Neomorph's proprietary molecular glue discovery platform to expedite the identification and validation of new small-molecule therapeutics for Alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 29, 2024

                            Lead Product(s) : Molecular Glue Degrader-based Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Recipient : Neomorph

                            Deal Size : $1,450.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biogen's Felzartamab Receives FDA Breakthrough Designation For Kidney Transplant

                            Details : MOR202 (felzartamab) is an investigational monoclonal antibody designed to specifically target and deplete CD38+ cells. It is being evaluated for late AMR in kidney transplant recipients.

                            Product Name : MOR202

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 09, 2024

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth